By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


F2G Ltd 

The Manchester Incubator Building
Grafton Street
Manchester    M139XX  United Kingdom
Phone: 44-0-161-606-7250 Fax: 44-0-161-606-7251


F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system. As a result serious fungal infections continue to increase. The focus at F2G is to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates. Through its proprietary genomics technology and antifungal screening activities F2G has identified a number of novel chemical series with potent antifungal activity. These novel series form the basis of the F2G development pipeline. Currently F2G is advancing its F3 series of anti mould compounds. This is a novel class of antifungal agent, which acts through a completely new mechanism different from all currently marketed drugs. The F3 series displays highly potent activity against clinically relevant aspergilli and many other important pathogenic moulds. F2G has a dedicated team of experienced scientists from a wide variety of research and drug development backgrounds supported by an experienced management group with many years experience of drug development within the Pharmaceutical industry.




CEO: Ian Nicholson

Key Statistics

Ownership: Private

Web Site: F2G


Company News
F2G Receives European Orphan Drug Designation For Its Lead Candidate F901318 1/9/2017 11:02:27 AM
F2G Announces The Appointment Of John H. Rex, MD, FACP To The Position Of Chief Medical Officer 12/5/2016 10:57:31 AM
F2G Announces Publication Of Initial F901318 Data In Scientific Journal PNAS 10/26/2016 7:43:11 AM
F2G Announces The Appointment Of Ralf Schmid To The Position Of Chief Financial Officer 7/11/2016 6:20:35 AM
Backed by Novartis AG (NVS) and Novo Nordisk A/S (NVO), UK Biotech F2G Bags $60 Million 6/20/2016 5:53:12 AM
F2G Ltd Release: Adaptive Pathways 12/1/2015 11:30:23 AM
F2G License Cresset’s Forge To Complement Successful Consulting Projects 4/8/2015 10:53:53 AM
F2G Ltd, The UK-Based Antifungal Drug Discovery And Development Company, Today Announced A Major Funding Award From The Technology Strategy Board’s Biomedical Catalyst 9/9/2014 10:06:23 AM
F2G Ltd, The UK-Based Antifungal Drug Discovery And Development Company, Today Announces Commencement Of A Phase 1 Single Ascending Dose Study Of A Novel Antifungal Agent, F901318. 9/2/2014 4:07:07 PM
F2G Ltd and the University of Manchester Announce a New €6.1 Million Project to Develop New Antifungal Agents to Treat Resistant Fungal Infections 6/25/2013 10:14:17 AM